SCHEMBL7101942

SCHEMBL7101942

CCS(=O)(=O)Nc1cccc(Cc2cn(S(=O)(=O)N(C)C)cn2)c1OC

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 4/20 0.38
FGFR1 P11362 1/20 0.34
FGFR2 P21802 1/20 0.34
FGFR4 P22455 1/20 0.34
FGFR3 P22607 1/20 0.34
KDR P35968 1/20 0.34
HTT P42858 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
KDM4E B2RXH2 1/20 0.33
NR3C1 P04150 2/20 0.33
LMNA P02545 2/20 0.32
HPGD P15428 2/20 0.32
HSD17B10 Q99714 1/20 0.32
PSIP1 O75475 1/20 0.32
ALDH1A1 P00352 1/20 0.31
MRGPRX1 Q96LB2 1/20 0.31
CBX7 O95931 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7510881 0.82 FGFR1 (0.35) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL7103262 0.78 SMN1; SMN2 (0.34) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL7103434 0.76 FGFR1 (0.31) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL7098549 0.75 BRAF (0.33) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL7104778 0.74 PDE10A (0.42) PDE10AHTTSMN1; SMN2NR3C1LMNA
SCHEMBL7098113 0.74 SMN1; SMN2 (0.39) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL7172007 0.71 KDM4E (0.32) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL12256780 0.69 HTR6 (0.33) PDE10AFGFR1FGFR2FGFR4FGFR3
SCHEMBL22075719 0.69 MEN1 (0.41) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL7097377 0.68 TDP1 (0.39) SMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073850-A1 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use ABBOTT LABORATORIES 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073850-A1 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use ADRA1D, ADRB1, ADRA1A PDE10A 250/4885FGFR1 1165/4885FGFR2 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.